Lauren Richards
Interventional Cardiology · Phoenix, AZNPI 1508250531
Payments from drug & device makers
Across 153 payments — averaging $128.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acist Medical Systems, Inc.$7K
- Boston Scientific$4K
- Abbott$2K
- Medtronic$1K
- Amgen$752
- Johnson & Johnson$691
- plus $4K from 25 others
What the payments were for
- Consulting fees$5,60028%
- Travel & lodging$1,7799%
- Food & beverage$11,00356%
- Education$1,3107%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acist Medical Systems, Inc. | 21 | $7,137 |
| Boston Scientific | 20 | $3,735 |
| Abbott | 18 | $2,118 |
| Medtronic(2 entities) | 8 | $1,034 |
| Amgen(2 entities) | 11 | $752 |
| Johnson & Johnson | 9 | $691 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 10 | $585 |
| Abiomed | 4 | $374 |
| Shockwave Medical, Inc | 2 | $329 |
| Cardiovascular Systems Inc. | 3 | $322 |
| Philips North America LLC | 3 | $315 |
| Astellas Pharma US Inc | 3 | $298 |
| AstraZeneca | 4 | $284 |
| Kestra Medical Technology Services, Inc. | 2 | $256 |
| Novo Nordisk | 2 | $204 |
| Boehringer Ingelheim | 4 | $191 |
| W. L. Gore & Associates, Inc. | 2 | $175 |
| Medical Device Business Services, Inc. | 3 | $145 |
| Bayer | 1 | $125 |
| Veryan Medical Incorporated | 2 | $112 |
| Actelion Pharmaceuticals US, Inc. | 3 | $85 |
| Novartis | 4 | $84 |
| Chiesi USA, Inc. | 1 | $84 |
| Pfizer | 4 | $78 |
| Atricure, Inc. | 1 | $43 |
| Irhythm Technologies, Inc. | 2 | $34 |
| Alnylam Pharmaceuticals Inc. | 2 | $34 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $20 |
| Impulse Dynamics (USA) Inc. | 1 | $18 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- HD-IVUS$5,764
- GENERAL VASCULAR ACCESS$2,433
- CVI SYSTEMS$858
- XARELTO$615
- CARDIOMEMS$422
- SYNERGY$379
- Repatha$376
- Dragonfly OCT$302
- LifeVest$294
- Endurant$289
- Assure WCD$256
- Impella$241
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$217
- RESOLUTE ONYX$214
- Ensite Cardiac Mapping System$208
- EnSite Precision Cardiac Mapping System$208
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$198
- COREVALVE EVOLUT R$190
- Diamondback Coronary$172
- COROFLOW$172
How this compares
$19,693 in reported general payments places this provider in the 60th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $14,608 |
| JardianceEmpagliflozin | 12 | $6,892 |
| Rosuvastatin Calcium | 11 | $497 |
| Metoprolol Tartrate | 14 | $224 |
| Metoprolol Succinate | 16 | $156 |
| Carvedilol | 14 | $138 |
| Losartan Potassium | 18 | $119 |
| Furosemide | 19 | $81 |
| Atorvastatin Calcium | 15 | $63 |
| Lisinopril | 21 | $63 |
| Amlodipine Besylate | 11 | $14 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $78 | $14,60812 claims |
| Boehringer IngelheimJardiance | $191 | $6,89212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Phoenix
- Paul SorajjaPhoenix$8.8M
- Timothy ByrnePhoenix$2.1M
- Mohamad LazkaniPhoenix$1.1M
- Parminder SinghPhoenix$854K
- Akil LoliPhoenix$506K
- Haidar YassinPhoenix$457K
- Michael WhitePhoenix$417K
- Nezar FallujiPhoenix$348K
- Floyd FortuinPhoenix$263K
- Nishant GuptaPhoenix$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.